Mark E. Dudley

46.4k total citations · 18 hit papers
114 papers, 29.3k citations indexed

About

Mark E. Dudley is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Mark E. Dudley has authored 114 papers receiving a total of 29.3k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 88 papers in Immunology and 39 papers in Genetics. Recurrent topics in Mark E. Dudley's work include CAR-T cell therapy research (90 papers), Immunotherapy and Immune Responses (73 papers) and Virus-based gene therapy research (36 papers). Mark E. Dudley is often cited by papers focused on CAR-T cell therapy research (90 papers), Immunotherapy and Immune Responses (73 papers) and Virus-based gene therapy research (36 papers). Mark E. Dudley collaborates with scholars based in United States, Malaysia and Canada. Mark E. Dudley's co-authors include Steven A. Rosenberg, Nicholas P. Restifo, John R. Wunderlich, James C. Yang, Richard A. Morgan, Paul F. Robbins, Richard M. Sherry, James Chih‐Hsin Yang, Donald E. White and Carolyn M. Laurençot and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Mark E. Dudley

112 papers receiving 28.7k citations

Hit Papers

Cancer Regression and Autoimmunity in Patients After Clon... 1998 2026 2007 2016 2002 2006 2010 2011 1998 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
    2002 2.2k citations Mark E. Dudley, John R. Wunderlich et al. Science profile →
  2. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
    2006 2.0k citations Richard A. Morgan, Mark E. Dudley et al. Science profile →
  3. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
    2010 1.9k citations Richard A. Morgan, James C. Yang et al. profile →
  4. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
    2011 1.6k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. Clinical Cancer Research profile →
  5. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
    1998 1.5k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. profile →
  6. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    2009 1.4k citations Mojgan Ahmadzadeh, Laura A. Johnson et al. profile →
  7. Adoptive immunotherapy for cancer: harnessing the T cell response
    2012 1.3k citations Nicholas P. Restifo, Mark E. Dudley et al. profile →
  8. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
    2014 1.3k citations Eric Tran, Simon Turcotte et al. Science profile →
  9. Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    2008 1.2k citations Steven A. Rosenberg, Nicholas P. Restifo et al. profile →
  10. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
    2011 1.1k citations Mark E. Dudley, Steven A. Feldman et al. profile →
  11. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    2010 1.0k citations Mark E. Dudley, Steven A. Feldman et al. profile →
  12. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
    2008 1.0k citations Mark E. Dudley, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  13. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
    2010 791 citations Maria R. Parkhurst, James C. Yang et al. profile →
  14. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
    2014 772 citations Alena Gros, Paul F. Robbins et al. profile →
  15. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
    2014 585 citations Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research profile →
  16. Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients
    2003 534 citations Mark E. Dudley, John R. Wunderlich et al. profile →
  17. Adoptive-cell-transfer therapy for the treatment of patients with cancer
    2003 531 citations Mark E. Dudley, Steven A. Rosenberg profile →
  18. Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
    2015 506 citations Sanja Stevanović, Lindsey M. Draper et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark E. Dudley United States 58 23.5k 20.2k 6.8k 5.6k 2.9k 114 29.3k
James C. Yang United States 60 15.3k 0.7× 12.0k 0.6× 5.7k 0.8× 4.1k 0.7× 2.9k 1.0× 140 20.9k
Paul F. Robbins United States 81 20.3k 0.9× 21.3k 1.1× 8.9k 1.3× 4.1k 0.7× 1.3k 0.5× 179 29.0k
Richard A. Morgan United States 53 13.3k 0.6× 8.1k 0.4× 7.0k 1.0× 6.5k 1.2× 2.7k 0.9× 124 18.7k
Gianpietro Dotti United States 84 19.3k 0.8× 10.4k 0.5× 7.7k 1.1× 6.4k 1.1× 7.8k 2.7× 287 26.5k
John R. Wunderlich United States 54 15.8k 0.7× 14.8k 0.7× 4.8k 0.7× 3.4k 0.6× 1.2k 0.4× 121 21.1k
Renier J. Brentjens United States 59 15.3k 0.7× 6.8k 0.3× 5.2k 0.8× 4.4k 0.8× 4.8k 1.7× 198 18.4k
Udai S. Kammula United States 46 14.0k 0.6× 10.2k 0.5× 4.2k 0.6× 2.7k 0.5× 1.1k 0.4× 89 18.2k
Michael Kalos United States 39 11.7k 0.5× 6.0k 0.3× 4.9k 0.7× 4.1k 0.7× 2.8k 1.0× 97 15.5k
Maryalice Stetler‐Stevenson United States 57 8.9k 0.4× 6.2k 0.3× 4.3k 0.6× 2.3k 0.4× 1.7k 0.6× 230 15.8k
Barbara Savoldo United States 66 14.0k 0.6× 6.5k 0.3× 4.4k 0.7× 4.8k 0.8× 3.8k 1.3× 207 16.6k

Countries citing papers authored by Mark E. Dudley

Since Specialization
Citations

This map shows the geographic impact of Mark E. Dudley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Dudley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Dudley more than expected).

Fields of papers citing papers by Mark E. Dudley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Dudley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Dudley. The network helps show where Mark E. Dudley may publish in the future.

Co-authorship network of co-authors of Mark E. Dudley

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Dudley. A scholar is included among the top collaborators of Mark E. Dudley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Dudley. Mark E. Dudley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Ling, Richard A. Morgan, Joal D. Beane, et al.. (2015). Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research. 21(10). 2278–2288. 332 indexed citations
2.
Stevanović, Sanja, Lindsey M. Draper, Michelle M. Langhan, et al.. (2015). Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology. 33(14). 1543–1550. 506 indexed citations breakdown →
3.
Chandran, Smita S., Biman C. Paria, Abhishek K. Srivastava, et al.. (2014). Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. Clinical Cancer Research. 21(3). 534–543. 39 indexed citations
4.
Robbins, Paul F., Sadik H. Kassim, Thai L.N. Tran, et al.. (2014). A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research. 21(5). 1019–1027. 585 indexed citations breakdown →
5.
Lu, Yong‐Chen, Xin Yao, Jessica S. Crystal, et al.. (2014). Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. Clinical Cancer Research. 20(13). 3401–3410. 304 indexed citations
6.
Tran, Eric, Simon Turcotte, Alena Gros, et al.. (2014). Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science. 344(6184). 641–645. 1278 indexed citations breakdown →
7.
Gros, Alena, Simon Turcotte, John R. Wunderlich, et al.. (2012). Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma. Clinical Cancer Research. 18(19). 5212–5223. 73 indexed citations
8.
Parkhurst, Maria R., John P. Riley, Mark E. Dudley, & Steven A. Rosenberg. (2011). Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression. Clinical Cancer Research. 17(19). 6287–6297. 367 indexed citations
9.
Rosenberg, Steven A., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2011). Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research. 17(13). 4550–4557. 1603 indexed citations breakdown →
10.
Dudley, Mark E., Colin Gross, Michelle M. Langhan, et al.. (2010). CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. Clinical Cancer Research. 16(24). 6122–6131. 245 indexed citations
11.
Dudley, Mark E., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2008). Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology. 26(32). 5233–5239. 1017 indexed citations breakdown →
12.
Morgan, Richard A., Mark E. Dudley, John R. Wunderlich, et al.. (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science. 314(5796). 126–129. 1961 indexed citations breakdown →
13.
Johnson, Laura A., Bianca Heemskerk, Daniel J. Powell, et al.. (2006). Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes. The Journal of Immunology. 177(9). 6548–6559. 240 indexed citations
14.
Huang, Jianping, Mona El‐Gamil, Mark E. Dudley, et al.. (2004). T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product. The Journal of Immunology. 172(10). 6057–6064. 80 indexed citations
15.
Zhou, Juhua, Mark E. Dudley, Steven A. Rosenberg, & Paul F. Robbins. (2004). Selective Growth, In Vitro and In Vivo, of Individual T Cell Clones from Tumor-Infiltrating Lymphocytes Obtained from Patients with Melanoma. The Journal of Immunology. 173(12). 7622–7629. 45 indexed citations
16.
Robbins, Paul F., Mark E. Dudley, John R. Wunderlich, et al.. (2004). Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy. The Journal of Immunology. 173(12). 7125–7130. 375 indexed citations
17.
Morgan, Richard A., Mark E. Dudley, Yik Y. L. Yu, et al.. (2003). High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens. The Journal of Immunology. 171(6). 3287–3295. 175 indexed citations
18.
Monsurrò, Vladia, Dirk Nagorsen, Ena Wang, et al.. (2002). Functional Heterogeneity of Vaccine-Induced CD8+ T Cells. The Journal of Immunology. 168(11). 5933–5942. 68 indexed citations
19.
Monsurrò, Vladia, Ainhoa Pérez‐Díez, Mark E. Dudley, et al.. (2001). Kinetics of TCR Use in Response to Repeated Epitope-Specific Immunization. The Journal of Immunology. 166(9). 5817–5825. 47 indexed citations
20.
Surman, Deborah R., Mark E. Dudley, Willem W. Overwijk, & Nicholas P. Restifo. (2000). Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen. The Journal of Immunology. 164(2). 562–565. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James C. Yang Breakdown of academic impact, for papers by Paul F. Robbins Breakdown of academic impact, for papers by Richard A. Morgan Breakdown of academic impact, for papers by Gianpietro Dotti Breakdown of academic impact, for papers by John R. Wunderlich Breakdown of academic impact, for papers by Renier J. Brentjens Breakdown of academic impact, for papers by Udai S. Kammula Breakdown of academic impact, for papers by Michael Kalos Breakdown of academic impact, for papers by Maryalice Stetler‐Stevenson Breakdown of academic impact, for papers by Barbara Savoldo
Rankless by CCL
2026